StockData
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. (DSGN) stock

DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$9.84−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $615.80MP/E –Yield –

Design Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Design Therapeutics's total assets was $215.13M at Jun 30, 2026. For fiscal 2025 it was $226.20M, down 10.3% from the year before. The highest annual figure on record is $390.56M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$226.20M-10.3%
FY2024Dec 31, 2024$252.09M-13.0%
FY2023Dec 31, 2023$289.64M-15.1%
FY2022Dec 31, 2022$341.14M-12.7%
FY2021Dec 31, 2021$390.56M+969.6%
FY2020Dec 31, 2020$36.52M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$215.13M-3.5%
Q1 FY2026Mar 31, 2026$230.44M-3.0%
Q4 FY2025Dec 31, 2025$226.20M-10.3%
Q3 FY2025Sep 30, 2025$211.77M-19.1%
Q2 FY2025Jun 30, 2025$222.89M-17.3%
Q1 FY2025Mar 31, 2025$237.48M-14.8%
Q4 FY2024Dec 31, 2024$252.09M-13.0%
Q3 FY2024Sep 30, 2024$261.63M-12.8%
Q2 FY2024Jun 30, 2024$269.58M-13.5%
Q1 FY2024Mar 31, 2024$278.79M-14.1%
Q4 FY2023Dec 31, 2023$289.64M-15.1%
Q3 FY2023Sep 30, 2023$299.87M-15.4%
Q2 FY2023Jun 30, 2023$311.63M-15.3%
Q1 FY2023Mar 31, 2023$324.74M-14.3%
Q4 FY2022Dec 31, 2022$341.14M-12.7%
Q3 FY2022Sep 30, 2022$354.57M-11.4%
Q2 FY2022Jun 30, 2022$367.93M-9.2%
Q1 FY2022Mar 31, 2022$378.80M-8.0%
Q4 FY2021Dec 31, 2021$390.56M+969.6%
Q3 FY2021Sep 30, 2021$400.35M–
Q2 FY2021Jun 30, 2021$405.15M–
Q1 FY2021Mar 31, 2021$411.85M–
Q4 FY2020Dec 31, 2020$36.52M–

More Design Therapeutics figures

See a number that looks wrong?